aslan
pharmaceuticals
develop
next
generation
dhodh
inhibitor
autoimmune
conditions
aslan
believes
potential
potent
oral
inhibitor
dhodh
currently
development
autoimmune
disease
times
potent
inhibiting
dhodh
enzyme
teriflunomide
aslan
appoints
neurologist
professor
gavin
giovannoni
scientific
advisor
establish
clinical
development
strategy
multiple
sclerosis
nanomolar
potency
also
assessed
potential
novel
therapeutic
viruses
singapore
globe
newswire
aslan
pharmaceuticals
nasdaq
asln
immunology
focused
biopharmaceutical
company
developing
innovative
treatments
transform
lives
patients
today
announced
plans
develop
next
generation
inhibitor
dihydroorotate
dehydrogenase
dhodh
autoimmune
conditions
multiple
sclerosis
ms
highly
selective
potent
inhibitor
human
dhodh
ic
nm
shown
times
potent
inhibiting
dhodh
enzyme
cell
free
assays
first
generation
inhibitor
teriflunomide
preclinical
studies
shown
efficacious
animal
models
ms
autoimmune
diseases
based
specificity
potency
favourable
safety
profile
identified
earlier
clinical
studies
aslan
believes
promising
candidate
development
diseases
pressing
need
differentiated
convenient
treatment
options
exists
dr
carl
firth
chief
executive
officer
aslan
pharmaceuticals
said
following
review
data
generated
discussions
experts
field
believe
potential
best
class
profile
potent
oral
dhodh
inhibitor
targeting
autoimmune
indications
current
need
differentiated
therapeutic
approach
ms
deliver
improved
efficacy
addresses
risks
toxicity
associated
classes
drug
inhibition
dhodh
established
mechanism
treatment
autoimmune
conditions
notably
multiple
sclerosis
rrms
first
generation
dhodh
inhibitors
limited
efficacy
like
many
treatment
options
rrms
associated
toxicities
requiring
safety
monitoring
make
less
suited
long
term
treatment
options
shown
well
tolerated
doses
mg
day
subjects
across
phase
phase
clinical
studies
suitable
oral
dosing
aslan
appointed
renowned
neurologist
professor
gavin
giovannoni
chair
neurology
blizard
institute
barts
london
school
medicine
dentistry
scientific
advisor
company
work
clinical
development
plan
company
expects
share
details
early
professor
gavin
giovannoni
scientific
advisor
aslan
added
new
effective
treatment
approaches
improved
safety
efficacy
convenience
highly
sought
ms
community
potency
favourable
safety
profile
make
promising
next
generation
dhodh
inhibitor
look
forward
working
team
define
novel
clinical
development
strategies
benefit
aslan
previously
observed
activity
dengue
zika
viruses
recently
determined
nanomolar
potency
vero
cells
ec
nm
aslan
currently
assessing
potential
treatment
viral
infections
provide
update
clinical
development
plans
determined
aslan
completed
phase
study
testing
aml
following
internal
strategic
review
noting
changes
aml
treatment
landscape
aslan
focusing
future
development
autoimmune
disease
media
ir
contacts
emma
thompson
spurwing
communications
tel
email
aslan
robert
uhl
westwicke
partners
tel
email
aslan
pharmaceuticals
aslan
pharmaceuticals
nasdaq
asln
immunology
focused
biopharmaceutical
company
developing
innovative
treatments
transform
lives
patients
led
senior
management
team
extensive
experience
global
development
commercialisation
aslan
clinical
portfolio
comprised
monoclonal
therapy
developed
atopic
dermatitis
immunology
indications
plans
develop
autoimmune
disease
additional
information
please
visit
forward
looking
statements
release
contains
statements
statements
based
current
beliefs
expectations
management
aslan
pharmaceuticals
limited
affiliates
company
statements
may
include
limited
statements
regarding
company
business
strategy
clinical
development
plans
company
plans
develop
autoimmune
disease
viral
infections
safety
efficacy
company
plans
expected
timing
respect
clinical
trials
clinical
preclinical
study
results
company
estimates
projections
statements
based
management
current
assumptions
expectations
future
events
trends
affect
may
affect
company
business
strategy
operations
financial
performance
inherently
involve
significant
known
unknown
risks
uncertainties
actual
results
timing
events
could
differ
materially
anticipated
statements
result
risks
uncertainties
include
without
limitation
risk
factors
described
company
securities
exchange
commission
filings
reports
commission
file
including
company
form
filed
securities
exchange
commission
sec
april
statements
statements
historical
fact
statements
words
believe
may
might
could
aim
estimate
continue
anticipate
intend
expect
plan
negative
terms
similar
expressions
convey
uncertainty
future
events
outcomes
intended
identify
estimates
projections
statements
estimates
projections
statements
speak
date
made
except
extent
required
law
company
undertakes
obligation
update
review
estimate
projection
statement
